At a glance
ClinicalIndex Comparison RecordN/ACompleted· 35 enrolled
Drug / intervention
Vivity Extended Depth of Focus intraocular lens (IOL)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the AcrySof® Vivity Intraocular Lens With a Target of Slight Myopia in the Non-dominant Eye
In Brief
A clinical study evaluating Vivity Extended Depth of Focus intraocular lens (IOL) for Cataract. Completed, enrolled 35 participants across 1 site.
Detailed Summary
The objective is to assess binocular distance-corrected near (40 cm) visual acuity of patients after uneventful cataract surgery with bilateral implantation of the AcrySof® Vivity Intraocular lens (IOL) when the non-dominant eye is targeted for slight myopia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartJul 2020
First PostedJul 2020
Primary CompletionJun 2021
TodayJul 2026
First PostedJul 22, 2020
Enrollment StartJul 17, 2020
Primary CompletionJun 10, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.9 years ago
Interventions
Vivity Extended Depth of Focus intraocular lens (IOL)device
Bilateral implantation of the Vivity lens after cataract surgery, with slight myopia planned in the non-dominant eye.